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Abstract
Introduction—Health-related quality of life (HRQoL) is reduced among persons with 
haemophilia. Little is known about how HRQoL varies with complications of haemophilia such as 
inhibitors and joint disease. Estimates of preference-based HRQoL measures are needed to model 
the cost-effectiveness of prevention strategies.
Aim—We examined the characteristics of a national sample of persons with severe haemophilia A 
for associations with two preference-based measures of HRQoL.
Methods—We analysed utility weights converted from EuroQol 5 Dimensions (EQ-5D) and the 
Short Form 6 Dimensions (SF-6D) scores from 1859 males aged ≥14 years with severe 
haemophilia A treated at 135 US haemophilia treatment centres in 20052011. Bivariate and 
regression analyses examined age-group-specific associations of HRQoL with inhibitor status, 
overweight/obesity, number of bleeds, viral infections, indicators of liver and joint disease, and 
severe bleeding at the time of the first HRQoL measurement.
Results—Overall mean HRQoL utility weight values were 0.71 using the SF-6D and 0.78 using 
the EQ-5D. All studied patient characteristics except for overweight/obesity were significantly 
associated with HRQoL in bivariate analyses. In a multivariate analysis, only joint disease was 
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significantly associated with utility weights from both HRQoL measures and across all age groups. 
After adjustment for joint disease and other variables, the presence of an inhibitor was not 
significantly associated with HRQoL scores from either of the standardized assessment tools.
Conclusion—Clinically significant complications of haemophilia, especially joint disease, are 
strongly associated with HRQoL and should be accounted for in studies of preference-based health 
utilities for people with haemophilia.
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1 | INTRODUCTION
Haemophilia is a rare coagulation disorder occurring in 1 in 10 000 births that results from 
the lack of either of two proteins, called factors, necessary for the formation of a normal 
blood clot. Deficiency of factor VIII (FVIII), called haemophilia A, is the most common 
form. Therapy involves the intravenous administration of clotting factor concentrate (CFC) 
either in response to a bleeding episode or prophylactically to prevent these episodes. In 
about 20%–30% of individuals, an antibody (referred to as an inhibitor) to the infused 
clotting factor develops that renders treatment with CFC ineffective against bleeding.1 Those 
with inhibitors have increased morbidity2 and mortality,3 and treatment for bleeding 
episodes with alternative CFCs called bypassing agents is extremely costly.4, 5
A number of studies have assessed the burden of haemophilia on health-related quality of 
life (HRQoL).6, 7 A recent review summarized 18 studies of health status utility values 
(HSUVs) in haemophilia patients, most of which used the EuroQol EQ-5D or the SF-6D 
based on the Rand Short Form questionnaire; no study used both measures.8 A previous 
analysis of HSUVs in 425 patients with severe haemophilia A from four European countries 
excluded patients who had an inhibitor.9 SF-6D scores decreased with increasing age and 
with a combined measure of joint disease and frequency of bleeding. Only two studies 
reported HSUVs for males with an inhibitor relative to those with the same level of severity 
of haemophilia A but without an inhibitor.10, 11
The purpose of this study was to use EQ-5D and SF-6D data collected on males with severe 
haemophilia A to calculate utility weights adjusted for demographic and clinical 
characteristics and for the presence of complications such as bleeding and liver disease to 
determine the independent effect of joint disease and an inhibitor on preference-based 
HRQoL. Data collected from the same subjects using both instruments provided the 
opportunity to evaluate the consistency of the results between the instruments.
2 | MATERIALS ANDMETHODS
From May 1998 through September 2011, people with haemophilia and other bleeding 
disorders receiving care in one of 135 haemophilia treatment centres (HTCs) in the USA 
were offered the opportunity to participate in the Centers for Disease Control and Prevention 
(CDC)’s Universal Data Collection (UDC) system.12 The project was approved by 
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Institutional Review Boards at each institution, and all patients (or parents of minor 
children) gave informed consent for participation.
2.1 | Data collection
HTC staff collected data at annual comprehensive clinic visits. Date of birth (used to 
calculate age at the time of the visit) and self-identified race and ethnicity data were 
collected at the initial UDC visit. For the analysis, a combined race/ethnicity variable was 
created with four levels: non-Hispanic white, non-Hispanic black, Hispanic, and other race 
ethnicities. Other sociodemographic data, including type of health insurance and whether the 
participant was employed or a student, were collected at each UDC visit. Clinical 
information collected during visits included measurements of height and weight; the type of 
treatment regimen (prophylaxis vs episodic); the highest inhibitor titre measured since the 
last UDC visit; whether the patient was on an immune tolerance treatment regimen; the 
number of joint, muscle or other bleeds experienced in the previous 6 months; the presence 
of signs or symptoms of liver disease (e.g, jaundice, ascites, varices), elevated liver enzymes, 
or evidence of previous infection with hepatitis B or C; the presence of a target joint 
(following the UDC definition as 4 or more bleeds in the same joint in the previous 6 
months); the number of days missed from work or school due to a joint problem; use of a 
cane or other assistive device for ambulation; and self-reported current activity level. The 
presence of HIV infection was determined on the basis of blood testing performed at the 
CDC laboratory as part of the surveillance.12
2.2 | Data analysis
For the analysis, we converted height and weight to body mass index (BMI) by dividing 
weight by height squared and categorized body weight as normal (BMI<25 kg/m2), 
overweight (BMI=25–29.9 kg/m2) or obese (BMI≥30 kg/m2) for patients aged ≥20 years or 
according to CDC BMI charts for patients aged <20 years.13 Only patients who had a recent 
inhibitor titre >1 Bethesda Unit or who were on an immune tolerance treatment regimen at 
the time of the visit were defined as having an inhibitor for the study. Insurance type was 
collapsed into two categories: commercial vs any other type of insurance or none.
We created three indicators for the following outcomes based on the empirical distribution of 
the present data:
• Severe bleeding was defined as ≥5 joint or total bleeds in the previous 6 months 
or as having one or more target joints (a joint with ≥4 bleeds in the previous 6 
months);
• Liver disease was defined as the presence of either signs/symptoms of liver 
disease, or elevated liver enzymes, or hepatitis B- or C-positive serologic status;
• Joint disease was defined as having a decreased activity level (either has 
limitations in or requires assistance with school/work, recreation and self-care), 
or ≥10 missed days of work or school due to a joint problem,14 or continuous use 
of a cane or a wheelchair for ambulation.
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Beginning in 2005, UDC participants aged ≥14 years could optionally complete a HRQoL 
questionnaire that incorporated the EQ-5D (EuroQol Group, Rotterdam, The Netherlands) 
and the SF-12v2® (QualiMetric, Lincoln, RI, USA) health surveys as well as the CDC 
HRQOL-04 “Healthy Days” (available at: https://www.cdc.gov/hrqol/hrqol14_measure.htm) 
instrument. The first completed questionnaire was used for those who completed more than 
one questionnaire, and data on other characteristics and outcomes were taken from the UDC 
visit at which the questionnaire was completed.
Conversion of the raw survey scores to HSUVs for each survey was accomplished using 
computer programs that applied country-specific weights to the survey question response 
levels. The EQ-5D HSUVs were derived using a US population value set15 (using software 
authored by James W. Shaw and available at: https://www.ahrq.gov/professionals/clinicians-
providers/resources/rice/ceoutc.html#Euro-Qol), whereas the SF-6D HSUVs were derived 
from the SF® health survey using the original UK. population value set16 (using software 
licensed from Sheffield University Enterprises Ltd., Sheffield, UK) as a US value set was not 
available.
2.3 | Statistical analysis
Data from all UDC participants with severe haemophilia A completing at least one HRQoL 
questionnaire were included in the analyses. Because the HSUVs for participants were not 
normally distributed, Wilcoxon score comparisons using nonparametric regression analyses 
were used to assess differences in utility values between levels of the sociodemographic and 
clinical characteristics for statistical significance.
Multiple linear regression analyses were used to compare mean HSUVs for those with and 
without an inhibitor adjusted for other patient characteristics. Because the results of 
regression analyses using either the actual utility values (parametric) or the ranks of the 
utility values (nonparametric) were virtually identical, only the results of the parametric 
multiple linear regression analyses are reported. Collinearity diagnostics revealed no 
indication of multicollinearity between variables; however, statistical interaction between 
age and several of the variables was identified. Therefore, the results of regression analyses 
were stratified by three age groups: 14–20, 21–44 and 45+ years to allow for potential age 
differences in influences of the studied risk factors on HRQoL.
All analyses used SAS statistical software (SAS Institute, Cary, NC, USA), and P-values ≤.
05 were considered statistically significant. Any differences in SF-6D scores <0.03 and 
differences in EQ-5D scores <0.04 were considered to be not “minimally important” and 
hence not of clinical significance. The minimally important difference (MID) for a patient-
reported outcome measure is the smallest difference that a patient would be likely to 
perceive as beneficial.17 In the case of multi-attribute utility instruments like the SF-6D and 
the EQ-5D, the MID is measured as the smallest difference in HSUV associated with a one-
step change in the underlying health state classification system.18 A US study that used that 
approach found that the mean MID was 0.027 for the SF-6D and 0.040 for the EQ-5D using 
the US preference function or value set.18
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3 | RESULTS
The study population comprised 1859 males with severe haemophilia A with at least one 
completed HRQoL survey. One-third of patients were under age 21 years and one-half 
between 21 and 44 years old (Table 1). Compared to the US population,19 Hispanic ethnicity 
was under-represented. One-half had commercial insurance, while one-third had public 
(Medicare or Medicaid) insurance. Two-thirds were employed or attended school. Nearly 
half were overweight or obese. Nearly 40% were on a prophylactic regimen, and 6.7% of the 
patients had a current inhibitor. About one-fourth were HIV-infected, two-thirds had an 
indicator of liver disease, and one-half had joint disease or severe bleeding (Table 1). The 
respondents represented 51.6% of the 3603 otherwise eligible patients during the same time 
period. Those who completed the questionnaire were somewhat younger, less likely to be a 
minority and less likely to be uninsured than the non-respondents. Respondents also less 
often had inhibitors than did non-respondents.
In bivariate analyses, sociodemographic, treatment and clinical characteristics except body 
adiposity were significantly associated with at least one of the two HSUVs (Table 1). The 
average HSUVs were generally higher for the EQ-5D measure than for the SF-6D, but the 
relative differences in average HSUVs among levels of the characteristics were similar. 
Average HSUVs decreased with age but increased for patients with commercial vs other 
types of insurance, those who were students or employed, those who were on prophylaxis, 
those who were not HIV-infected, and those without evidence of severe bleeding, joint 
disease or liver disease.
Average HSUVs were slightly lower for the SF-6D (0.04 lower) and EQ-5D (0.03 lower) 
measures in patients with a current inhibitor than in those without an inhibitor (Table 1). The 
magnitudes of both differences were of marginal clinical significance, although the 
difference in the SF-6D HSUV exceeds the MID, whereas the EQ-5D HSUV does not. All 
other differences in Table 1 that were statistically significant were of clinical significance, 
with differences ≥0.04 exceeding the MID for both measures.
One patient characteristic, a dichotomous variable for joint disease, was independently and 
negatively associated with HSUVs in multivariate analyses (indicated by negative values for 
the coefficients) across both measures and all three age groups (Table 2).
The only other characteristic that was significantly associated with HRQoL across both 
measures within two age groups was student/employment status. Among patients under age 
45 years, being in school or employed was associated with significantly better HRQoL, with 
absolute adjusted differences of 0.04–0.07 in HSUVs. Having commercial insurance relative 
to any other insurance type was significantly positively associated with HRQoL among those 
aged 21–44 years. It was significantly associated with HRQoL in the other two age groups 
for only one of the two measures in each group. It was of clinical significance only in the 
older age group.
Among those aged 14–20 years, current use of prophylaxis was associated with statistically 
significantly higher EQ-5D HSUVs, although the difference was not clinically significant, 
and it was not statistically significantly associated with SF-6D HSUVs. The remaining 
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variables did not have statistically significant associations with HRQoL. In particular, the 
presence of an inhibitor was not statistically significantly associated with HRQoL in any age 
group after adjustment for other factors (P=0.5–0.7).
The adjusted mean HSUVs are presented for patients with and without an inhibitor in Table 
3. Although the mean EQ-5D HSUVs were uniformly higher than those from the SF-6D, 
differences were very small, and the HSUVs differed very little by inhibitor status or across 
age groups.
4 | DISCUSSION
Among a large group of patients with severe haemophilia A, we found relatively consistent 
effects on HRQoL associated with several sociodemographic and clinical characteristics as 
assessed by two preference-based HRQoL measures, the EQ-5D and SF-6D. Most 
importantly, patients with indicators of joint disease had substantially decreased HRQoL 
within each age group. Adolescents and adults under age 45 who were students or were 
employed had significantly better HSUVs. Patients with commercial insurance generally had 
higher HSUVs than those with other forms of insurance but the association was too modest 
to be of clinical significance for those under age 45.18
The impact of joint disease on HRQoL is marked. Our results suggest that this risk factor 
alone is primarily responsible for the decreased HRQoL observed in persons with severe 
haemophilia. The adjusted and unadjusted impact of joint disease on EQ-5D HSUVs is 
virtually the same, about −0.13 (Tables 1 and 2). That is almost equal in absolute magnitude 
to the 0.15 difference in mean EQ-5D HSUVs observed between the 14–20 and 45+ year 
age groups. An important implication is that the presence of joint disease should be 
accounted for in analyses of the effects of other variables on HRQoL among persons with 
haemophilia, especially when using the EQ-5D, which includes a mobility component.
Of interest was the finding that our severe bleeding indicator was not generally 
independently associated with HSUVs in multivariate analyses. A likely explanation is that 
individuals with more severe bleeding typically develop joint disease. After adjusting for the 
presence of joint disease, bleeding does not appear to have a significant direct impact on 
HRQoL. Rather, severe bleeding in haemophilia appears to primarily influence HRQoL 
indirectly through the development of joint disease.
The negative effect of an inhibitor on HRQoL was surprisingly modest. Although unadjusted 
HSUVs for people with an inhibitor differed statistically significantly from those without an 
inhibitor, HSUVs after accounting for other patient characteristics did not differ statistically 
between groups.
Several other characteristics, including liver disease, BMI and HIV infection, likewise were 
not independently associated with HRQoL. BMI had no association with HRQoL even 
without controlling for confounding, whereas persons with either liver disease or HIV had 
significantly worse HRQoL on average before controlling for confounding (Table 1). After 
controlling for other patient characteristics, though, neither factor had a significant 
association with HRQoL. In a preliminary multivariate regression analysis for the pooled 
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sample, liver disease was strongly negatively associated with HRQoL (results not reported), 
but that association essentially disappeared when the analysis was stratified by age group 
(Table 2). One possible explanation is that liver disease is strongly associated with older age, 
particularly over age 45 years, among whom HRQoL is generally lower than that among 
individuals in the younger age groups. Within age groups, liver disease was not associated 
with HRQoL.
Individuals using prophylaxis had significantly better average HRQoL than those who 
received on-demand factor, and prophylaxis status was slightly more strongly associated 
with HRQoL than was severe bleeding (Table 1). However, younger subjects were much 
more likely than older subjects to be on prophylaxis and to have higher HSUVs. After 
adjusting for patient characteristics, prophylaxis status was not associated with HRQoL past 
age 20 years. Prophylaxis was weakly positively associated with HRQoL in the youngest 
age group, but only for one measure, the EQ-5D. Cross-sectional associations of current 
prophylaxis status and HRQoL typically do not differ statistically significantly, but the 
profile of prophylaxis over time may be more important.8 Primary prophylaxis, initiated 
before the onset of severe bleeds, greatly reduces the risk of joint disease, the primary 
predictor of HRQoL in patients with severe haemophilia.20
Comparisons of our findings on inhibitors and preference-based HRQoL with those of 
previous studies are complicated by differences in study design. Wasserman et al.10 used a 
standard gamble approach to directly elicit HSUVs for hypothetical health states, one of 
which was having a lifelong inhibitor and chronic joint damage; it is not possible to separate 
out the effect of an inhibitor from that of joint damage.
Noone, et al.11 reported a mean EQ-5D HSUV of 0.798 for 13 males with an inhibitor, 
which was higher than in our study, but the authors did not report a pooled HSUV for males 
without an inhibitor. Neufeld et al.21 reported a mean EQ-5D HSUV of 0.72 for 18 US 
adults with an inhibitor that was intermediate between the adjusted values of 0.74 and 0.75 
in the two younger age groups and the value of 0.71 among the oldest patients with an 
inhibitor in our study. However, HSUVs were not adjusted for other comorbidities.
Study limitations should be considered when interpreting our results. First, our results reflect 
the measurement of HRQoL at one point in time and may be influenced by short-term events 
occurring in the patient’s life unrelated to the studied variables. Because we consider the 
possible influence of these other events on our findings to be random and non-differential, 
these events are unlikely to have systematically affected our results except to decrease 
statistical power in detecting differences among groups.
Second, because the completion of the questionnaire was voluntary, not all patients 
participated. Non-response bias in HRQoL surveys is often associated with less participation 
by people who are older, more socio-economically deprived and more likely to have 
comorbid conditions.22 To the extent that non-responders in this survey may have had worse 
HRQoL, our results may overstate HRQoL overall. In particular, if those with inhibitors who 
did not respond had worse HRQoL, our findings may underestimate the effect of an inhibitor 
on quality of life.
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Third, many of the patients that we studied with a more severe bleeding phenotype were 
likely to have chosen to utilize prophylaxis, which is readily available to patients in this 
clinical setting. Therefore, to the extent that subjects who chose not to use prophylaxis 
despite frequent bleeding were less concerned with this complication, we may have 
underestimated the effect of frequent bleeding episodes on HRQoL.
Finally, all of the patients participating in the surveillance receive care in the US HTC 
Network and have access to comprehensive haemophilia care and a variety of therapies 
including immune tolerance therapy treatment and bypassing products. It is possible that 
access to these therapies may have minimized any effects of inhibitors on HRQoL.
In conclusion, we found no consistent effect of an inhibitor on HRQoL after adjusting for 
the effects of other comorbid conditions, especially joint disease. The adjusted HSUVs we 
report may be useful in calculations of quality-adjusted life years (QALYs) for cost-
effectiveness or cost-utility studies needed to assess improvements in health for people with 
haemophilia resulting from therapeutic strategies such as prophylaxis.
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